
-
Agios Pharmaceuticals Inc. NasdaqGS:AGIO Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Location: 88 Sidney Street, Cambridge, MA, 02139, United States | Website: https://www.agios.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
849.5M
Cash
893.4M
Avg Qtr Burn
-100.4M
Short % of Float
7.66%
Insider Ownership
1.60%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tibsovo (Ivosidenib) (IDH1m inhibitor) Details AML (Acute Myeloid Leukemia) | Approved Quarterly sales | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Sickle cell disease, Anemia | Approved Quarterly sales | |
VORANIGO (Vorasidenib) Details Glioma, Brain tumor | Approved Quarterly sales | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Beta thalessemia | PDUFA Approval decision | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Pyruvate Kinase Deficiency | NDA Submission | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Sickle cell disease, Anemia | Phase 3 Data readout | |
Tebapivat (AG-946) Details Myelodysplastic syndrome | Phase 2b Update | |
Tebapivat Details Sickle cell disease, Blood disorder | Phase 2 Initiation | |
AG-181 Details Phenylketonuria | Phase 1 Data readout | |
AG-236 Details Polycythemia vera | IND Submission |